R&D News | pharmaphorum

News

Financing figures reveal resilience of UK biotech in 2023

2023 was a tough year for biotechs with declines in private fundraising and public listings, but the UK industry stood up well under the pressure, according to new figures

News

CG Oncology is first biotech IPO of 2024, raising $380m

CG Oncology has taken the ribbon for the first biotech initial public offering (IPO) of the new year and its $380 million raise – which far outstrips the proceeds forecast

News

BARDA backs Locus phage therapy for resistant E coli

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in de

News

LEO says chronic hand eczema drug bests its only rival

Dermatology specialist LEO Pharma has built the case for its first-in-class chronic hand eczema (CHE) drug delgocitinib, saying it outperformed the only approved drug ther

News

BenevolentAI names pharma vet Jörg Möller as its new CEO

BenevolentAI’s search for a new chief executive has concluded with the appointment of industry bigwig Dr Jörg Möller to the role, four months after Joanna Shields stepped

News

Lilly trumpets early success with deafness gene therapy

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness

Financing figures reveal resilience of UK biotech in 2023

CG Oncology is first biotech IPO of 2024, raising $380m

BARDA backs Locus phage therapy for resistant E coli

LEO says chronic hand eczema drug bests its only rival

BenevolentAI names pharma vet Jörg Möller as its new CEO

Lilly trumpets early success with deafness gene therapy

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks